Savara (NASDAQ:SVRA) Reaches New 1-Year Low on Analyst Downgrade

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) reached a new 52-week low on Thursday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. HC Wainwright currently has a buy rating on the stock. Savara traded as low as $3.24 and last traded at $3.32, with a volume of 128515 shares traded. The stock had previously closed at $3.25.

Several other brokerages have also recently issued reports on SVRA. Evercore ISI reissued an "in-line" rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research note on Wednesday. JMP Securities reissued a "market outperform" rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.17.

Institutional Trading of Savara

Large investors have recently made changes to their positions in the business. Verition Fund Management LLC lifted its holdings in Savara by 83.5% during the third quarter. Verition Fund Management LLC now owns 114,495 shares of the company's stock worth $485,000 after acquiring an additional 52,084 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Savara by 24.7% during the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company's stock worth $34,302,000 after purchasing an additional 1,600,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock worth $533,000 after purchasing an additional 6,141 shares in the last quarter. MetLife Investment Management LLC raised its stake in Savara by 28.6% in the third quarter. MetLife Investment Management LLC now owns 66,907 shares of the company's stock valued at $284,000 after purchasing an additional 14,883 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company's stock valued at $109,000 after purchasing an additional 18,534 shares in the last quarter. Institutional investors own 87.93% of the company's stock.

Savara Stock Performance

The stock's 50-day moving average is $3.93 and its 200-day moving average is $4.21. The firm has a market capitalization of $525.08 million, a price-to-earnings ratio of -7.60 and a beta of 1.02. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). On average, analysts predict that Savara Inc will post -0.44 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.